Globus Medical Reports Second Quarter 2022 Results

Globus Medical

AUDUBON, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2022.

• Worldwide net sales were $263.6 million, an increase of 5.0% as reported, and an increase of 6.5% on a constant currency basis, compared to the second quarter of 2021

• GAAP net income for the quarter was $54.6 million

• GAAP diluted earnings per share (“EPS”) was $0.53 and non-GAAP diluted EPS was $0.56

• Non-GAAP adjusted EBITDA was $91.9 million, or 34.9% of net sales

“Our second quarter record sales grew 6.5% on a constant currency basis and accelerated from last quarter as we continue to make market share gains, despite headwinds of a difficult prior year comparative and unfavorable foreign currency fluctuations,” commented Dan Scavilla, President and CEO. “Our Enabling Technologies business had a record-breaking quarter, increasing 41.7% to $29.4 million, driven by strong robotic systems demand, as well as the initial roll-out of our highly anticipated Excelsius3D^TM imaging system. Globus Medical continues to be the innovative leader in helping patients with musculoskeletal disorders.”

Worldwide net sales for the second quarter of 2022 was $263.6 million, an as-reported increase of 5.0% over the second quarter of 2021, and an increase of 6.5% on a constant currency basis.  U.S. net sales for the second quarter of 2022, including robotics, increased by 4.7% compared to the second quarter of 2021. International net sales increased by 6.9% over the second quarter of 2021 on an as-reported basis, and an increase of 17.3% on a constant currency basis.

GAAP net income for the second quarter of 2022 was $54.6 million, an increase of 31.4% over the same period in the prior year. Diluted EPS for the second quarter was $0.53, compared to $0.40 for the second quarter of 2021. Non-GAAP diluted EPS for the second quarter of 2022 was in line with the same period in prior year at $0.56, and includes current period non-operating headwinds related to a higher effective tax rate and unfavorable foreign currency fluctuations.

Net cash provided by operating activities was $36.9 million, and non-GAAP free cash flow was $13.1 million for the second quarter of 2022. The Company remains debt free.

2022 Annual Guidance

The Company today reaffirmed its full year 2022 guidance of $1.025 billion in net sales and non-GAAP diluted earnings per share of $2.10.

Conference Call Information

Globus Medical will hold a teleconference to discuss its second quarter 2022 results with the investment community at 4:30 p.m. Eastern Time today. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at https://www.investors.globusmedical.com/news-events/events-webcasts.

To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The audio archive will be available after the call on the Investor page of the Globus Medical website.

About Globus Medical, Inc.

Based in Audubon, Pennsylvania, Globus Medical, Inc. was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.

Non-GAAP Financial Measures

To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), management uses certain non-GAAP financial measures. For example, non-GAAP Adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation expense, provision for litigation, acquisition related costs/licensing, and acquisition of in-process research and development, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense. Our management also uses non-GAAP Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Acquisition related costs/licensing represents the change in fair value of business-acquisition-related contingent consideration; costs related to integrating recently acquired businesses, including but not limited to costs to exit or convert contractual obligations, severance, and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees, as well as one-time licensing fees. Acquisition of in-process research and development represents the expensing of acquired assets with no alternative future use and related fees.

In addition, for the period ended June 30, 2022 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP Diluted Earnings Per Share, which represent net income and diluted earnings per share excluding the provision for litigation, amortization of intangibles, acquisition related costs/licensing, acquisition of in-process research and development, and the tax effects of all of the foregoing adjustments. The tax effect adjustment represents the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net income. The tax impact of the non-GAAP adjustments is calculated based on the consolidated effective tax rate on a GAAP basis, applied to the non-GAAP adjustments, unless the underlying item has a materially different tax treatment, in which case the estimated tax rate applicable to the adjustment is used. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of litigation, amortization of intangibles, acquisition related costs/licensing, acquisition of in-process research and development, and the tax effects of all of the foregoing adjustments, which we believe are not reflective of underlying business trends. Additionally, for the period ended June 30, 2022 and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, the non-GAAP measure of constant currency net sales growth is calculated by translating current year net sales at the same average exchange rates in effect during the applicable prior year period. We believe constant currency net sales growth provides insight to the comparative increase or decrease in period net sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates.

Non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, free cash flow and constant currency net sales growth are not calculated in conformity with U.S. GAAP. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with U.S. GAAP. These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, free cash flow and constant currency net sales growth may differ from that of other companies and therefore may not be comparable.

Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the U.S. Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the U.S. Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)

		Three Months Ended								Six Months Ended
		June 30,								June 30,
(In thousands, except per share amounts)		2022				2021				2022				2021
Net sales		$	263,648			$	251,016			$	494,197			$	478,360
Cost of goods sold			68,470				63,846				127,637				118,873
Gross profit			195,178				187,170				366,560				359,487
Operating expenses:
Research and development			17,395				15,547				34,807				30,471
Selling, general and administrative			106,718				107,254				207,466				205,145
Provision for litigation			—				—				2,341				(94	)
Amortization of intangibles			4,393				4,623				8,905				9,397
Acquisition related costs			(1,104	)			13,870				(1,180	)			14,144
Total operating expenses			127,402				141,294				252,339				259,063
Operating income/(loss)			67,776				45,876				114,221				100,424
Other income/(expense), net
Interest income/(expense), net			2,476				2,541				5,019				5,253
Foreign currency transaction gain/(loss)			(1,107	)			209				(1,498	)			(71	)
Other income/(expense)			1,395				307				1,696				521
Total other income/(expense), net			2,764				3,057				5,217				5,703
Income/(loss) before income taxes			70,540				48,933				119,438				106,127
Income tax provision			15,950				7,388				26,764				19,253
Net income/(loss)		$	54,590			$	41,545			$	92,674			$	86,874
Other comprehensive income/(loss), net of tax:
Unrealized gain/(loss) on marketable securities			(5,031	)			(774	)			(13,859	)			(2,440	)
Foreign currency translation gain/(loss)			(3,170	)			1,026				(4,737	)			(3,087	)
Total other comprehensive income/(loss), net of tax			(8,201	)			252				(18,596	)			(5,527	)
Comprehensive income/(loss)		$	46,389			$	41,797			$	74,078			$	81,347
Earnings per share:
Basic		$	0.54			$	0.41			$	0.92			$	0.87
Diluted		$	0.53			$	0.40			$	0.90			$	0.84
Weighted average shares outstanding:
Basic			100,671				100,449				101,136				100,159
Diluted			102,884				103,475				103,480				102,931

GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)

		June 30,				December 31,
(In thousands, except share and per share values)		2022				2021
ASSETS
Current assets:
Cash and cash equivalents		$	150,772			$	193,069
Short-term marketable securities			257,238				250,378
Accounts receivable, net of allowances of $4,182 and $4,962, respectively			192,814				164,436
Inventories			266,043				237,001
Prepaid expenses and other current assets			18,579				18,417
Income taxes receivable			5,722				1,215
Total current assets			891,168				864,516
Property and equipment, net of accumulated depreciation of $321,999 and $305,575, respectively			238,882				221,076
Long-term marketable securities			473,663				562,475
Intangible assets, net			59,131				68,660
Goodwill			182,702				179,708
Other assets			34,007				36,334
Deferred income taxes			35,159				24,494
Total assets		$	1,914,712			$	1,957,263
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable		$	34,195			$	21,955
Accrued expenses			82,543				91,168
Income taxes payable			3,471				1,046
Business acquisition liabilities			12,623				11,770
Deferred revenue			13,185				12,025
Payable to broker			—				2,200
Total current liabilities			146,017				140,164
Business acquisition liabilities, net of current portion			55,691				58,755
Deferred income taxes			2,511				4,314
Other liabilities			11,400				12,642
Total liabilities			215,619				215,875
Equity:
Class A common stock; $0.001 par value. Authorized 500,000,000 shares; issued and outstanding 77,037,205 and 79,113,916 shares at June 30, 2022 and December 31, 2021, respectively			77				79
Class B common stock; $0.001 par value. Authorized 275,000,000 shares; issued and outstanding 22,430,097 and 22,430,097 shares at June 30, 2022 and December 31, 2021, respectively			22				22
Additional paid-in capital			581,907				553,787
Accumulated other comprehensive income/(loss)			(25,368	)			(6,772	)
Retained earnings			1,142,455				1,194,272
Total equity			1,699,093				1,741,388
Total liabilities and equity		$	1,914,712			$	1,957,263

GLOBUS MEDICAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)

		Six Months Ended
		June 30,
(In thousands)		2022				2021
Cash flows from operating activities:
Net income		$	92,674			$	86,874
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			33,764				36,287
Amortization of premium (discount) on marketable securities			3,208				1,131
Write-down for excess and obsolete inventories, net			4,068				5,000
Stock-based compensation expense			15,989				15,330
Allowance for doubtful accounts			(528	)			590
Change in fair value of business acquisition liabilities			(1,390	)			14,128
Change in deferred income taxes			(7,939	)			(1,783	)
(Gain)/loss on disposal of assets, net			200				191
Payment of business acquisition related liabilities			(1,099	)			—
(Increase)/decrease in:
Accounts receivable			(30,224	)			(25,587	)
Inventories			(31,421	)			(6,024	)
Prepaid expenses and other assets			1,268				845
Increase/(decrease) in:
Accounts payable			12,375				2,737
Accrued expenses and other liabilities			(7,408	)			3,559
Income taxes payable/receivable			(1,964	)			(10,519	)
Net cash provided by/(used in) operating activities			81,573				122,759
Cash flows from investing activities:
Purchases of marketable securities			(179,096	)			(293,092	)
Maturities of marketable securities			170,572				131,739
Sales of marketable securities			66,655				58,154
Purchases of property and equipment			(43,724	)			(22,058	)
Acquisition of businesses, net of cash acquired and purchases of intangible and other assets			(1,175	)			—
Net cash provided by/(used in) investing activities			13,232				(125,257	)
Cash flows from financing activities:
Payment of business acquisition liabilities			(3,553	)			(3,105	)
Proceeds from exercise of stock options			11,331				35,597
Repurchase of common stock			(144,493	)			—
Net cash provided by/(used in) financing activities			(136,715	)			32,492
Effect of foreign exchange rates on cash			(387	)			(608	)
Net increase/(decrease) in cash and cash equivalents			(42,297	)			29,386
Cash and cash equivalents at beginning of period			193,069				239,397
Cash and cash equivalents at end of period		$	150,772			$	268,783
Supplemental disclosures of cash flow information:
Income taxes paid		$	36,696			$	31,597
Purchases of property and equipment included in accounts payable and accrued expenses		$	5,019			$	3,537

Supplemental Financial Information

Net Sales by Product Category:

		Three Months Ended						Six Months Ended
		June 30,						June 30,
(In thousands)		2022			2021			2022			2021
Musculoskeletal Solutions		$	234,242		$	230,263		$	451,644		$	442,679
Enabling Technologies			29,406			20,753			42,553			35,681
Total net sales		$	263,648		$	251,016		$	494,197		$	478,360

Liquidity and Capital Resources:

		June 30,			December 31,
(In thousands)		2022			2021
Cash and cash equivalents		$	150,772		$	193,069
Short-term marketable securities			257,238			250,378
Long-term marketable securities			473,663			562,475
Total cash, cash equivalents and marketable securities		$	881,673		$	1,005,922

The following tables reconcile GAAP to Non-GAAP financial measures.

Non-GAAP Adjusted EBITDA Reconciliation Table:

	Three Months Ended								Six Months Ended
	June 30,								June 30,
(In thousands, except percentages)	2022				2021				2022				2021
Net income/(loss)	$	54,590			$	41,545			$	92,674			$	86,874
Interest (income)/expense, net		(2,476	)			(2,541	)			(5,019	)			(5,253	)
Provision for income taxes		15,950				7,388				26,764				19,253
Depreciation and amortization		16,927				19,130				33,764				36,287
EBITDA		84,991				65,522				148,183				137,161
Stock-based compensation expense		7,837				7,632				15,989				15,330
Provision for litigation		—				—				2,341				(94	)
Acquisition related costs/licensing		(943	)			14,624				(286	)			15,507
Adjusted EBITDA	$	91,885			$	87,778			$	166,227			$	167,904
Net income/(loss) as a percentage of net sales		20.7	%			16.6	%			18.8	%			18.2	%
Adjusted EBITDA as a percentage of net sales		34.9	%			35.0	%			33.6	%			35.1	%

Non-GAAP Net Income Reconciliation Table:

	Three Months Ended								Six Months Ended
	June 30,								June 30,
(In thousands)	2022				2021				2022				2021
Net income/(loss)	$	54,590			$	41,545			$	92,674			$	86,874
Provision for litigation		—				—				2,341				(94	)
Amortization of intangibles		4,393				4,623				8,905				9,397
Acquisition related costs/licensing		(943	)			14,624				(286	)			15,507
Tax effect of adjusting items		(780	)			(2,906	)			(2,441	)			(4,060	)
Non-GAAP net income/(loss)	$	57,260			$	57,886			$	101,192			$	107,624

Non-GAAP Diluted Earnings Per Share Reconciliation Table:

	Three Months Ended								Six Months Ended
	June 30,								June 30,
(In thousands)	2022				2021				2022				2021
Diluted earnings per share, as reported	$	0.53			$	0.40			$	0.90			$	0.84
Provision for litigation		—				—				0.02				—
Amortization of intangibles		0.05				0.04				0.09				0.09
Acquisition related costs/licensing		(0.01	)			0.14				(0.00	)			0.15
Tax effect of adjusting items		0.00				(0.03	)			(0.02	)			(0.04	)
Non-GAAP diluted earnings per share	$	0.56			$	0.56			$	0.98			$	1.05

*amounts might not add due to rounding

Non-GAAP Free Cash Flow Reconciliation Table:

	Three Months Ended								Six Months Ended
	June 30,								June 30,
(In thousands)	2022				2021				2022				2021
Net cash provided by operating activities	$	36,883			$	59,189			$	81,573			$	122,759
Purchases of property and equipment		(23,753	)			(8,386	)			(43,724	)			(22,058	)
Free cash flow	$	13,130			$	50,803			$	37,849			$	100,701

Non-GAAP Net Sales on a Constant Currency Basis Comparative Table:

		Three Months Ended						Reported			Currency Impact on				Constant Currency
		June 30,						Net Sales			Current				Net Sales
(In thousands, except percentages)		2022			2021			Growth			Period Net Sales				Growth
United States		$	225,280		$	215,119		4.7	%		$	—			4.7	%
International			38,368			35,897		6.9	%			(3,750	)		17.3	%
Total net sales		$	263,648		$	251,016		5.0	%		$	(3,750	)		6.5	%

		Six Months Ended						Reported			Currency Impact on				Constant Currency
		June 30,						Net Sales			Current				Net Sales
(In thousands, except percentages)		2022			2021			Growth			Period Net Sales				Growth
United States		$	421,683		$	408,436		3.2	%		$	—			3.2	%
International			72,514			69,924		3.7	%			(4,838	)		10.6	%
Total net sales		$	494,197		$	478,360		3.3	%		$	(4,838	)		4.3	%

Contact:
Brian Kearns
Senior Vice President, Business Development and Investor Relations
Phone: (610) 930-1800
Email: investors@globusmedical.com 
www.globusmedical.com